EZH2 and cancer stem cells: Fact or fiction?

Epigenomics

Volumn 3, Issue 2, 2011, Pages 127-128

  Crea, Francesco ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

cancer stem cells; cell culture; EZH2; polycomb; serum

Indexed keywords

POLO LIKE KINASE; TRANSCRIPTION FACTOR EZH2; UVOMORULIN;

CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL RENEWAL; CELL STRAIN MCF 7; DNA MODIFICATION; EDITORIAL; HISTONE METHYLATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION;

DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASTIC STEM CELLS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 79955146907     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.11.4     Document Type: Editorial

References (16)

1. Surface LE, Thornton SR, Boyer LA: Polycomb group proteins set the stage for early lineage commitment. Cell Stem Cell, 7, 288-298 (2010).
2. Aoki R, Chiba T, Miyagi S et al.: The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/ progenitor cells. J. Hepatol. 52, 854-863 (2010).
3. Varambally S, Dhanasekaran SM, Zhou M et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
4. Crea F, Mathews LA, Farrar WL, Hurt EM: Targeting prostate cancer stem cells. Anticancer Agents Med. Chem. 9, 1105-1113 (2009).
5. Suva ML, Riggi N, Janiszewska M et al.: EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69, 9211-9218 (2009).
6. Orzan F, Pellegatta S, Poliani L, et al, Enhancer of zeste 2 EzH2 is up-regulated in malignant gliomas and in glioma stem-like cells, Neuropathol. Appl. Neurobiol. 0.1111/j.1365-2990.2010.01132 2010 Epub ahead of print
7. Crea F, Hurt EM, Farrar WL: Clinical significance of Polycomb gene expression in brain tumors. Mol. Cancer 9, 265 (2010).
8. Wang H, Ouyang Y, Somers WG, Chia W, Lu B: Polo inhibits progenitor self-renewal and regulates Numb asymmetry by phosphorylating Pon. Nature 449, 96-100 (2007). (Pubitemid 47373766)
9. Yu J, Yu J, Rhodes DR et al.: A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67, 10657-10663 (2007). (Pubitemid 350145890)
10. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV: Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 5, 1886-1901 (2006). (Pubitemid 44435335)
11. Hurt EM, Farrar WL: Cancer stem cells: the seeds of metastasis? Mol. Interv. 8, 140-142 (2008).
12. Yasuda H, Soejima K, Watanabe H et al.: Distinct epigenetic regulation of tumor suppressor genes in putative cancer stem cells of solid tumors. Int. J. Oncol. 37, 1537-1546 (2010).
13. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL: CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 98, 756-765 (2008). (Pubitemid 351272625)
14. Dick JE: Looking ahead in cancer stem cell research. Nat. Biotechnol. 27, 44-46 (2009).
15. Cao Q, Yu J, Dhanasekaran SM et al.: Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27, 7274-7284 (2008).
16. Mathews LA, Hurt EM, Zhang X, Farrar WL: Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells. Mol. Cancer 9, 267 (2010).